West China School of Public Health and West China Fourth Hospital,
State Key Laboratory of Biotherapy,
West China School of Public Health and West China Fourth Hospital, State Key Laboratory of Biotherapy
Zhiming Li has not added Biography.
If you are Zhiming Li and would like to personalize this page please email our Author Liaison for assistance.
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Journal of hematology & oncology Mar, 2017 | Pubmed ID: 28298231
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.
Frontiers in oncology , 2021 | Pubmed ID: 34804937
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Cancer medicine Nov, 2022 | Pubmed ID: 35438258
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.
The Lancet. Haematology Jul, 2022 | Pubmed ID: 35772429
Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China.
Cancer medicine Feb, 2023 | Pubmed ID: 36106610
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2023 | Pubmed ID: 36735519
A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer/T-cell lymphoma.
American journal of hematology Jul, 2023 | Pubmed ID: 36970971
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Blood advances Aug, 2023 | Pubmed ID: 37078706
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
American journal of hematology Nov, 2023 | Pubmed ID: 37647123
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2024 | Pubmed ID: 38190117
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
Leukemia Apr, 2024 | Pubmed ID: 38378844
Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis.
British journal of haematology Sep, 2024 | Pubmed ID: 39327747
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.
Journal for immunotherapy of cancer Oct, 2024 | Pubmed ID: 39455094
Editorial: Epigenetic regulation of genome integrity and its implications in human diseases.
Frontiers in cell and developmental biology , 2024 | Pubmed ID: 39720006
A tale of two strands: Decoding chromatin replication through strand-specific sequencing.
Molecular cell Jan, 2025 | Pubmed ID: 39824166
Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study.
Oral oncology Mar, 2025 | Pubmed ID: 39952083
Multimodal Masked Autoencoder Based on Adaptive Masking for Vitiligo Stage Classification.
Journal of imaging informatics in medicine Apr, 2025 | Pubmed ID: 40301294
1Hormel Institute, University of Minnesota,
2West China School of Public Health and West China Fourth Hospital, State Key Laboratory of Biotherapy, Sichuan University,
3Institute for Cancer Genetics, Department of Pediatrics and Department of Genetics and Development, Columbia University Medical Center
Copyright © 2025 MyJoVE Corporation. 판권 소유